Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 16:11:720052.
doi: 10.3389/fonc.2021.720052. eCollection 2021.

Recurrence Patterns After IMRT/VMAT in Head and Neck Cancer

Heleen Bollen  1   2 , Julie van der Veen  1   2 , Annouschka Laenen  3 , Sandra Nuyts  1   2
Affiliations

Recurrence Patterns After IMRT/VMAT in Head and Neck Cancer

Heleen Bollen et al. Front Oncol. .

Abstract

Purpose: Intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), two advanced modes of high-precision radiotherapy (RT), have become standard of care in the treatment of head and neck cancer. The development in RT techniques has markedly increased the complexity of target volume definition and accurate treatment delivery. The aim of this study was to indirectly investigate the quality of current TV delineation and RT delivery by analyzing the patterns of treatment failure for head and neck cancer patients in our high-volume RT center.

Methods: Between 2004 and 2014, 385 patients with pharyngeal, laryngeal, and oral cavity tumors were curatively treated with primary RT (IMRT/VMAT). We retrospectively investigated locoregional recurrences (LRR), distant metastases (DM), and overall survival (OS).

Results: Median follow-up was 6.4 years (IQR 4.7-8.3 years) during which time 122 patients (31.7%) developed LRR (22.1%) and DM (17.7%). The estimated 2- and 5-year locoregional control was 78.2% (95% CI 73.3, 82.3) and 74.2% (95% CI 69.0, 78.8). One patient developed a local recurrence outside the high-dose volume and five patients developed a regional recurrence outside the high-dose volume. Four patients (1.0%) suffered a recurrence in the electively irradiated neck and two patients had a recurrence outside the electively irradiated neck. No marginal failures were observed. The estimated 2- and 5-year DM-free survival rates were 83.3% (95% CI 78.9, 86.9) and 80.0% (95% CI 75.2, 84.0). The estimated 2- and 5-year OS rates were 73.6% (95% CI 68.9, 77.8) and 52. 6% (95% CI 47.3, 57.6). Median OS was 5.5 years (95% CI 4.5, 6.7).

Conclusion: Target volume definition and treatment delivery were performed accurately, as only few recurrences occurred outside the high-dose regions and no marginal failures were observed. Research on dose intensification and identification of high-risk subvolumes might decrease the risk of locoregional relapses. The results of this study may serve as reference data for comparison with future studies, such as dose escalation or proton therapy trials.

Keywords: delineation; head and neck cancer; intensity-modulated radiotherapy; proton therapy; radiotherapy; recurrence; tumor resistance; volumetric modulated arc therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Site of first recurrence. Number of patients with a recurrence in the different sites. Overlapping circles show combination possibilities. There were one isolated local recurrence outside CTVp and one isolated regional recurrence outside CTVe. The numbers in the shaded area represent persistent tumors after the end of treatment, included in the total number of recurrences, e.g., 10 of 16 RR were persistent after treatment. CTVe, elective clinical target volume; DM, distant metastases; HNC, head and neck cancer; LR, local recurrence; RR, regional recurrence; SP, second primary.
Figure 2
Figure 2
Axial CT scan images of the only patient with a local recurrence outside of the high-dose volume. (A) The primary tumor originating in the vallecula and (B) CT scan of the local recurrence in the prelaryngeal space, approximately 1 cm caudal of the index tumor.
See this image and copyright information in PMC

References

    1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 32 Cancer Groups, 1990 to 2015. JAMA Oncol (2017) 3:524–48. doi: 10.1001/jamaoncol.2016.5688 - DOI - PMC - PubMed
    1. Pignon J-P, Maître A, Maillard E, Bourhis J. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomised Trials and 17,346 Patients. Radiother Oncol (2009) 92(1):4–14. doi: 10.1016/j.radonc.2009.04.014 - DOI - PubMed
    1. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or Accelerated Radiotherapy in Head and Neck Cancer: A Meta-Analysis. Lancet (2006) 368(9538):843–54. doi: 10.1016/S0140-6736(06)69121-6 - DOI - PubMed
    1. Nuyts S, Dirix P, Clement PMJ, Vander Poorten V, Delaere P, Schoenaers J, et al. Impact of Adding Concomitant Chemotherapy to Hyperfractionated Accelerated Radiotherapy for Advanced Head-And-Neck Squamous Cell Carcinoma. Int J Radiat Oncol (2009) 73(4):1088–95. doi: 10.1016/j.ijrobp.2008.05.042 - DOI - PubMed
    1. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-Sparing Intensity Modulated Versus Conventional Radiotherapy in Head and Neck Cancer (PARSPORT): A Phase 3 Multicenter Randomised Controlled Trial. Lancet Oncol (2011) 12(2):127–36. doi: 10.1016/S1470-2045(10)70290-4 - DOI - PMC - PubMed

LinkOut - more resources